BTK and B-cell chronic lymphocytic leukemia: Novel inhibitors of BCR-associated kinases (i.e., the BTK inhibitors ibrutinib, acalabrutinib, zanubrutinib, and pirtobrutinib and the PI3K inhibitor idelalisib) have been approved in the USA and Europe for relapsed CLL or first-line treatment of a CLL patient bearing a TP53 abnormality [6,7].